Aurobindo Pharma Limited
Aurobindo Pharma Limited (AUROPHARMA.NS) Stock Overview
Explore Aurobindo Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
703.6B
P/E Ratio
20.18
EPS (TTM)
$60.08
ROE
0.11%
AUROPHARMA.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Aurobindo Pharma Limited (AUROPHARMA.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 56.93, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1354.96.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 20.18 and a market capitalization of 703.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.